{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:33:24Z","timestamp":1784547204661,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research & Development Program of China","award":["2016YFC1307200"],"award-info":[{"award-number":["2016YFC1307200"]}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["ZYLX201607"],"award-info":[{"award-number":["ZYLX201607"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Municipal Administration of Hospitals Incubating Program","award":["PX2018064"],"award-info":[{"award-number":["PX2018064"]}]},{"name":"The Beijing Municipal Administration of Hospitals\u2019 Ascent Plan","award":["DFL20151801"],"award-info":[{"award-number":["DFL20151801"]}]},{"name":"The Capital's Funds for Health Improvement and Research","award":["CFH 2018-1-2121"],"award-info":[{"award-number":["CFH 2018-1-2121"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the population of postmenopausal patients with major depressive disorder (MDD), the superiority of serotonin-norepinephrine reuptake inhibitors (SNRIs) over selective serotonin reuptake inhibitors (SSRIs) has not yet been definitively proven. Consequently, a direct comparison of the efficacy of SSRIs and SNRIs in the treatment of postmenopausal depression could provide relevant data. The aim of this study was to compare the efficacy and safety of venlafaxine vs. fluoxetine in the treatment of postmenopausal MDD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was an 8-week, multicenter, randomized, single-blind, active-controlled trial conducted at a psychiatric hospital (Beijing Anding Hospital) and a general hospital (Beijing Chaoyang Hospital) between April 2013 and September 2017. The primary outcome measure was improving depressive symptoms (Hamilton Depression Rating Scale (HAMD-24) score). The secondary outcomes included the change of HAMD-24 anxiety\/somatization factor score and Clinical Global Impressions-Improvement (CGI-I) response rate. Safety was assessed by treatment-emergent adverse events (TEAEs) and laboratory tests. Efficacy was analyzed by using the full analysis set (FAS) following the modified intention-to-treat (mITT) principle. The primary endpoint measurements were analyzed using a mixed-effect model for repeated measures (MMRM) model with patients as a random-effect factor, treatment group as the independent variable, time as a repeated measure, and baseline covariates, using a first-order ante dependence covariance matrix.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 184 women were randomized. The full analysis set (FAS) included 172 patients (venlafaxine, <jats:italic>n<\/jats:italic>\u2009=\u200982; fluoxetine, <jats:italic>n<\/jats:italic>\u2009=\u200990). Over the 8-week study period, the reduction in HAMD-24 scores was significant (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) in both groups, while a significantly greater decline from baseline was observed in the venlafaxine group compared with the fluoxetine group (least-squares mean difference [95% CI]: \u2212\u20092.22 [\u2212\u20097.08, \u2212\u20090.41]), <jats:italic>P<\/jats:italic>\u00a0=\u00a00.001). The baseline-to-week-8 least-squares mean change of the anxiety\/somatization factor scores, CGI-I response rate were greater in the venlafaxine group than in the fluoxetine group (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The most frequent TEAEs (\u22655%) in both groups were nausea, somnolence, dizziness, headache, and dry mouth. There was no significant difference in the incidence of adverse events between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Venlafaxine was well tolerated and compared to fluoxetine, it led to a greater improvement in the treatment of postmenopausal MDD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinical Trials. gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">#NCT01824433<\/jats:ext-link>. The trial was registered on April 4, 2013.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03253-8","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T13:09:40Z","timestamp":1621429780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study"],"prefix":"10.1186","volume":"21","author":[{"given":"Jingjing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuequan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runsen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"3253_CR1","volume-title":"Depression in adults: the treatment and management of depression in adults (updated edition)","author":"National Collaborating Centre for Mental Health commissioned by the National Institute for Health and Care Excellence (NICE)","year":"2009","unstructured":"National Collaborating Centre for Mental Health commissioned by the National Institute for Health and Care Excellence (NICE). Depression in adults: the treatment and management of depression in adults (updated edition). London: NICE; 2009."},{"key":"3253_CR2","volume-title":"Practice guideline for the treatment of patients with major depressive disorder (third edition)","author":"AJ Gelenberg","year":"2010","unstructured":"Gelenberg AJ, Freeman MP, Markowitz JC. Practice guideline for the treatment of patients with major depressive disorder (third edition). Washington, D.C.: American Psychiatric Association; 2010."},{"key":"3253_CR3","volume-title":"Prevalence of Depression Among Adults Aged 20 and Over: United States, 2013\u20132016. NCHS Data Brief: 1\u20138","author":"DJ Brody","year":"2018","unstructured":"Brody DJ, Pratt LA, Hughes JP. Prevalence of Depression Among Adults Aged 20 and Over: United States, 2013\u20132016. NCHS Data Brief: 1\u20138; 2018."},{"key":"3253_CR4","volume-title":"Depression and Other Common Mental Disorders: Global Health Estimates","author":"World Health Organization","year":"2017","unstructured":"World Health Organization: Depression and Other Common Mental Disorders: Global Health Estimates. 2017."},{"issue":"3","key":"3253_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1017\/S0033291712001511","volume":"43","author":"AJ Ferrari","year":"2013","unstructured":"Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43(3):471\u201381. https:\/\/doi.org\/10.1017\/S0033291712001511.","journal-title":"Psychol Med"},{"issue":"2","key":"3253_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/13697137.2010.510912","volume":"14","author":"A Unsal","year":"2011","unstructured":"Unsal A, Tozun M, Ayranci U. Prevalence of depression among postmenopausal women and related characteristics. Climacteric. 2011;14(2):244\u201351. https:\/\/doi.org\/10.3109\/13697137.2010.510912.","journal-title":"Climacteric"},{"key":"3253_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jad.2014.12.061","volume":"175","author":"SJ Jung","year":"2015","unstructured":"Jung SJ, Shin A, Kang D. Hormone-related factors and post-menopausal onset depression: results from KNHANES (2010-2012). J Affect Disord. 2015;175:176\u201383. https:\/\/doi.org\/10.1016\/j.jad.2014.12.061.","journal-title":"J Affect Disord"},{"issue":"1","key":"3253_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JCP.0b013e3181c82717","volume":"30","author":"S Grigoriadis","year":"2010","unstructured":"Grigoriadis S, Bouffard BA, Kennedy S, Bagby RM, Joffe RT. A comparison of desipramine response in younger and older women. J Clin Psychopharmacol. 2010;30(1):80\u20132. https:\/\/doi.org\/10.1097\/JCP.0b013e3181c82717.","journal-title":"J Clin Psychopharmacol"},{"issue":"1\u20133","key":"3253_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jad.2006.02.010","volume":"93","author":"A Pinto-Meza","year":"2006","unstructured":"Pinto-Meza A, Usall J, Serrano-Blanco A, Suarez D, Haro JM. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Disord. 2006;93(1\u20133):53\u201360. https:\/\/doi.org\/10.1016\/j.jad.2006.02.010.","journal-title":"J Affect Disord"},{"issue":"3","key":"3253_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/JCP.0b013e3181dcb594","volume":"30","author":"SG Kornstein","year":"2010","unstructured":"Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol. 2010;30(3):294\u20139. https:\/\/doi.org\/10.1097\/JCP.0b013e3181dcb594.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"3253_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1176\/appi.psy.46.4.345","volume":"46","author":"VK Burt","year":"2005","unstructured":"Burt VK, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Stewart DE. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics. 2005;46(4):345\u201354. https:\/\/doi.org\/10.1176\/appi.psy.46.4.345.","journal-title":"Psychosomatics"},{"issue":"1","key":"3253_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/026988110101500102","volume":"15","author":"JK Melichar","year":"2001","unstructured":"Melichar JK, Haida A, Rhodes C, Reynolds AH, Nutt DJ, Malizia AL. Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. J Psychopharmacol (Oxford, England). 2001;15(1):9\u201312.","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"10","key":"3253_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14656566.2018.1491966","volume":"19","author":"JR Strawn","year":"2018","unstructured":"Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057\u201370. https:\/\/doi.org\/10.1080\/14656566.2018.1491966.","journal-title":"Expert Opin Pharmacother"},{"key":"3253_CR14","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3389\/fgene.2019.00898","volume":"10","author":"Z Ungvari","year":"2019","unstructured":"Ungvari Z, Tarantini S, Yabluchanskiy A, Csiszar A. Potential adverse cardiovascular effects of treatment with fluoxetine and other selective serotonin reuptake inhibitors (SSRIs) in patients with geriatric depression: implications for Atherogenesis and Cerebromicrovascular dysregulation. Front Genet. 2019;10:898. https:\/\/doi.org\/10.3389\/fgene.2019.00898.","journal-title":"Front Genet"},{"issue":"12 Pt 2","key":"3253_CR15","first-page":"21","volume":"41","author":"M Hamilton","year":"1980","unstructured":"Hamilton M. Rating depressive patients. J Clin Psychiatr. 1980;41(12 Pt 2):21\u20134.","journal-title":"J Clin Psychiatr"},{"issue":"8","key":"3253_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archpsyc.1988.01800320058007","volume":"45","author":"JB Williams","year":"1988","unstructured":"Williams JB. A structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatr. 1988;45(8):742\u20137. https:\/\/doi.org\/10.1001\/archpsyc.1988.01800320058007.","journal-title":"Arch Gen Psychiatr"},{"key":"3253_CR17","volume-title":"Handbook of Psychiatric Measures (1st ed). Edn","author":"W Guy","year":"2000","unstructured":"Guy W. Clinical global impressions (CGI) scale, modified. In: Rush JA, Task force for the handbook of psychiatric measures, editors. Handbook of Psychiatric Measures (1st ed). Edn. Washington, D.C.: American Psychiatric Association; 2000."},{"issue":"1","key":"3253_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0278-5846(95)00292-8","volume":"20","author":"M Dierick","year":"1996","unstructured":"Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro-Psychopharmacol Biol Psychiatry. 1996;20(1):57\u201371. https:\/\/doi.org\/10.1016\/0278-5846(95)00292-8.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"3","key":"3253_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0924-977X(01)00089-X","volume":"11","author":"F Martenyi","year":"2001","unstructured":"Martenyi F, Dossenbach M, Mraz K, Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol. 2001;11(3):227\u201332. https:\/\/doi.org\/10.1016\/S0924-977X(01)00089-X.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"3253_CR20","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1176\/appi.ajp.157.9.1445","volume":"157","author":"SG Kornstein","year":"2000","unstructured":"Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157(9):1445\u201352. https:\/\/doi.org\/10.1176\/appi.ajp.157.9.1445.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"3253_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00404-015-3900-1","volume":"293","author":"F Davari-Tanha","year":"2016","unstructured":"Davari-Tanha F, Soleymani-Farsani M, Asadi M, Shariat M, Shirazi M, Hadizadeh H. Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. Arch Gynecol Obstet. 2016;293(5):1007\u201313. https:\/\/doi.org\/10.1007\/s00404-015-3900-1.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"3253_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/gme.0b013e3181d88962","volume":"17","author":"CN Soares","year":"2010","unstructured":"Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause (New York, NY). 2010;17(4):700\u201311.","journal-title":"Menopause (New York, NY)"},{"issue":"2\u20133","key":"3253_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0014-2999(85)90684-3","volume":"115","author":"JT Haskins","year":"1985","unstructured":"Haskins JT, Moyer JA, Muth EA, Sigg EB. DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity. Eur J Pharmacol. 1985;115(2\u20133):139\u201346. https:\/\/doi.org\/10.1016\/0014-2999(85)90684-3.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"3253_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0024-3205(95)00209-O","volume":"57","author":"DT Wong","year":"1995","unstructured":"Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995;57(5):411\u201341. https:\/\/doi.org\/10.1016\/0024-3205(95)00209-O.","journal-title":"Life Sci"},{"issue":"2","key":"3253_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/00019442-200502000-00008","volume":"13","author":"OP Almeida","year":"2005","unstructured":"Almeida OP, Lautenschlager N, Vasikaram S, Leedman P, Flicker L. Association between physiological serum concentration of estrogen and the mental health of community-dwelling postmenopausal women age 70 years and over. Am J Geriatric Psychiatr. 2005;13(2):142\u20139. https:\/\/doi.org\/10.1097\/00019442-200502000-00008.","journal-title":"Am J Geriatric Psychiatr"},{"issue":"6","key":"3253_CR26","doi-asserted-by":"publisher","first-page":"774","DOI":"10.4088\/JCP.v66n0617","volume":"66","author":"ML Morgan","year":"2005","unstructured":"Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatr. 2005;66(6):774\u201380. https:\/\/doi.org\/10.4088\/JCP.v66n0617.","journal-title":"J Clin Psychiatr"},{"issue":"2","key":"3253_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00019442-199721520-00002","volume":"5","author":"LS Schneider","year":"1997","unstructured":"Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine collaborative study group. Am J Geriatric Psychiatr. 1997;5(2):97\u2013106. https:\/\/doi.org\/10.1097\/00019442-199721520-00002.","journal-title":"Am J Geriatric Psychiatr"},{"issue":"11","key":"3253_CR28","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/sj.npp.1300510","volume":"29","author":"LJ Smith","year":"2004","unstructured":"Smith LJ, Henderson JA, Abell CW, Bethea CL. Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacol. 2004;29(11):2035\u201345. https:\/\/doi.org\/10.1038\/sj.npp.1300510.","journal-title":"Neuropsychopharmacol"},{"issue":"3","key":"3253_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0024-3205(98)00255-0","volume":"63","author":"DP Holschneider","year":"1998","unstructured":"Holschneider DP, Kumazawa T, Chen K, Shih JC. Tissue-specific effects of estrogen on monoamine oxidase a and B in the rat. Life Sci. 1998;63(3):155\u201360. https:\/\/doi.org\/10.1016\/S0024-3205(98)00255-0.","journal-title":"Life Sci"},{"issue":"8","key":"3253_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.biopsych.2005.01.014","volume":"57","author":"C Gundlah","year":"2005","unstructured":"Gundlah C, Alves SE, Clark JA, Pai LY, Schaeffer JM, Rohrer SP. Estrogen receptor-beta regulates tryptophan hydroxylase-1 expression in the murine midbrain raphe. Biol Psychiatry. 2005;57(8):938\u201342. https:\/\/doi.org\/10.1016\/j.biopsych.2005.01.014.","journal-title":"Biol Psychiatry"},{"issue":"1\u20132","key":"3253_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.molbrainres.2004.12.011","volume":"135","author":"RL Sanchez","year":"2005","unstructured":"Sanchez RL, Reddy AP, Centeno ML, Henderson JA, Bethea CL. A second tryptophan hydroxylase isoform, TPH-2 mRNA, is increased by ovarian steroids in the raphe region of macaques. Brain Res Mol Brain Res. 2005;135(1\u20132):194\u2013203. https:\/\/doi.org\/10.1016\/j.molbrainres.2004.12.011.","journal-title":"Brain Res Mol Brain Res"},{"issue":"1","key":"3253_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neulet.2007.02.039","volume":"417","author":"BE Sumner","year":"2007","unstructured":"Sumner BE, Grant KE, Rosie R, Hegele-Hartung C, Fritzemeier KH, Fink G. Raloxifene blocks estradiol induction of the serotonin transporter and 5-hydroxytryptamine2A receptor in female rat brain. Neurosci Lett. 2007;417(1):95\u20139. https:\/\/doi.org\/10.1016\/j.neulet.2007.02.039.","journal-title":"Neurosci Lett"},{"issue":"2","key":"3253_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1017\/S1461145702002857","volume":"5","author":"A De Nayer","year":"2002","unstructured":"De Nayer A, Geerts S, Ruelens L, Schittecatte M, De Bleeker E, Van Eeckhoutte I, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol. 2002;5(2):115\u201320. https:\/\/doi.org\/10.1017\/S1461145702002857.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl 4","key":"3253_CR34","first-page":"4","volume":"60","author":"JP Feighner","year":"1999","unstructured":"Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatr. 1999;60(Suppl 4):4\u201311 discussion 12-13.","journal-title":"J Clin Psychiatr"},{"issue":"1","key":"3253_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/da.10045","volume":"16","author":"JR Davidson","year":"2002","unstructured":"Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depression Anxiety. 2002;16(1):4\u201313. https:\/\/doi.org\/10.1002\/da.10045.","journal-title":"Depression Anxiety"},{"issue":"1","key":"3253_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/13697130009167598","volume":"3","author":"A Bener","year":"2000","unstructured":"Bener A, Rizk DE, Shaheen H, Micallef R, Osman N, Dunn EV. Measurement-specific quality-of-life satisfaction during the menopause in an Arabian gulf country. Climacteric. 2000;3(1):43\u20139. https:\/\/doi.org\/10.3109\/13697130009167598.","journal-title":"Climacteric"},{"issue":"28","key":"3253_CR37","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.1200\/JCO.2005.11.181","volume":"23","author":"TJ Whelan","year":"2005","unstructured":"Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23(28):6931\u201340. https:\/\/doi.org\/10.1200\/JCO.2005.11.181.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3253_CR38","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jemermed.2011.05.040","volume":"43","author":"N Lutwak","year":"2012","unstructured":"Lutwak N, Dill C. A depressed post-menopausal woman. J Emergency Med. 2012;43(5):815\u20139. https:\/\/doi.org\/10.1016\/j.jemermed.2011.05.040.","journal-title":"J Emergency Med"},{"key":"3253_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jad.2013.12.011","volume":"156","author":"JJ Schuch","year":"2014","unstructured":"Schuch JJ, Roest AM, Nolen WA, Penninx BW, de Jonge P. Gender differences in major depressive disorder: results from the Netherlands study of depression and anxiety. J Affect Disord. 2014;156:156\u201363. https:\/\/doi.org\/10.1016\/j.jad.2013.12.011.","journal-title":"J Affect Disord"},{"issue":"11","key":"3253_CR40","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3346\/jkms.2015.30.11.1659","volume":"30","author":"JH Kim","year":"2015","unstructured":"Kim JH, Cho MJ, Hong JP, Bae JN, Cho SJ, Hahm BJ, et al. Gender differences in depressive symptom profile: Results from Nationwide general population surveys in Korea. J Korean Med Sci. 2015;30(11):1659\u201366. https:\/\/doi.org\/10.3346\/jkms.2015.30.11.1659.","journal-title":"J Korean Med Sci"},{"issue":"4","key":"3253_CR41","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/gme.0b013e3181d770a8","volume":"17","author":"SG Kornstein","year":"2010","unstructured":"Kornstein SG, Young EA, Harvey AT, Wisniewski SR, Barkin JL, Thase ME, et al. The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. Menopause (New York, NY). 2010;17(4):828\u201339.","journal-title":"Menopause (New York, NY)"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-021-03253-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T13:10:38Z","timestamp":1621429838000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03253-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03253-8","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of Beijing Anding Hospital and Beijing Chaoyang Hospital, respectively. The study was carried out according to the Declaration of Helsinki and the guidelines for good clinical practice. The trial was registered ( #NCT01824433) on April 4, 2013, prior to the study initiation. Written informed consent was obtained from all participants before the commencement of any study procedures. Patients were informed that they were free to withdraw from the trial at any time.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Gang Wang received research support from Pfizer and Merck & Co., Inc. The other authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}